BioSpace News Archive

The independent Data Monitoring Committee (DMC) of the COVA study recommends start of recruitment of Part 2 of the two-part Phase 2-3 Study

Biophytis SA announces that it plans to publicly file a registration statement on Form F-1 with the U.S. Securities and Exchange Commission today in relation to a proposed initial public offering of ordinary shares in the form of American Depositary Shares in the United States and proposed Nasdaq listing in connection therewith.

BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that Health Canada has confirmed that 2-bromo-LSD is not a controlled substance.

Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference

International medical imaging IT and cybersecurity company Sectra has received an order from Institut Bergonié for its digital pathology solution.

Forbion, a leading European life sciences venture capital firm, announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc., a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 and other RNA viruses.

Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, announced its launch backed by $80 million Series C financing led by Abingworth LLP.

Cue Health Inc. announced that its molecular, point-of-care COVID-19 Tests are being distributed to five additional states, including Colorado, Minnesota, Pennsylvania, Rhode Island and Utah, as part of the joint $481 million program with the U.S. Department of Health and Human Services and the Department of Defense.

Occlutech, a privately-held company, announced that the U.S Food and Drug Administration has granted the Company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator for heart failure patients with preserved or reduced ejection fraction.

Gritstone Oncology, Inc., a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, announced that it is advancing development of a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants.